Addressing a major unmet need in cancer cachexia
Significant unmet need: Cancer cachexia remains a high-burden condition with no current effective treatments available, despite strong regulatory and payer recognition of the unmet need
Attractive market opportunity: Well defined market exists today and is expected to grow meaningfully, creating a significant commercial opportunity in an underpenetrated market
Differentiated science: NT1000™ is the only therapy for cancer cachexia that relieves patient pain while improving quality of life
Focused commercial strategy: Initial launch targets key cities with a phased and scalable global expansion